Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.35 +7.5% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.28 −2.3% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.59 −1.2% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.35 +7.5% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.28 −2.3% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.59 −1.2%
Other Routine +

CRYSVITA(TM) Now Publicly Reimbursed for the Treatment of Adults with XLH in Four Provinces and Federal Non-Insured Health Benefits Program

Kyowa Kirin Expands CRYSVITA Access, But Oncology Pipeline Risks Loom

By The Northwire Desk — AI Analysis May 06, 2026 · 08:00 4151
Executive Summary
  • May 6, 2026 (Most Recent): Kyowa Kirin Canada announced public drug coverage for CRYSVITA (burosumab) in Ontario, British Columbia, Saskatchewan, Alberta, and the federal Non-Insured Health Benefits program. Coverage now extends to adults with X-linked hypophosphatemia (XLH), previously limited to pediatric patients. This follows successful pan-Canadian Pharmaceutical Alliance (pCPA) negotiations resulting in a letter of intent.
  • April 24, 2026: Kyowa Kirin and Kura Oncology initiated a Japanese Phase 2 registration-directed trial for ziftomenib (KOMZIFTI) in relapsed/refractory NPM1-mutated AML. This follows FDA approval of the drug in November 2025.
  • January 30, 2026: Kyowa Kirin ended its collaboration with Amgen for rocatinlimab (atopic dermatitis), regaining full control of development and commercialization. Phase 3 data met endpoints; regulatory filing planned for H1 2026.
  • December 8, 2025: Kura Oncology reported combination data for ziftomenib with venetoclax and azacitidine in AML, showing robust efficacy (86% composite complete remission in newly diagnosed NPM1-mutated AML).
  • November 13, 2025: FDA granted full approval of KOMZIFTI (ziftomenib) for relapsed/refractory NPM1-mutated AML. Kura leads U.S. commercialization; Kyowa Kirin handles non-U.S. markets.
  • October 28, 2025: OTL-200 received Orphan Regenerative Medicine Product Designation in Japan for metachromatic leukodystrophy (MLD).
Material Impact
  • The most recent news regarding CRYSVITA reimbursement is a confirmation of previously anticipated outcomes. The pCPA letter of intent was public knowledge, making the final formulary listing an execution milestone rather than a surprise catalyst.
  • Expanding coverage to adults in major Canadian provinces (ON, BC, AB, SK) increases the addressable market for CRYSVITA beyond pediatrics, which is positive for revenue stability. However, as this follows known negotiations, it lacks the "unexpected" quality required for a Material - Positive rating under strict risk-averse criteria.
  • The historical progression shows a strong pipeline execution: FDA approval of Ziftomenib (Nov 2025) followed by combination data (Dec 2025) and now Japanese trial initiation (April 2026). This validates the partnership with Kura Oncology but adds complexity to Kyowa Kirin's commercial obligations outside the U.S.
  • The takeover of Rocatinlimab from Amgen (Jan 2026) is a strategic shift that increases Kyowa Kirin's operational burden and cost exposure, though it secures long-term rights to a Phase 3 asset.
  • Overall, the news cycle demonstrates consistent progress but lacks a singular "Game Changer" event in the most recent release compared to the FDA approval earlier in the year. The reimbursement update is incremental revenue growth rather than a fundamental valuation reset.
4151 · Price
Company Overview
  • Company: Kyowa Kirin (Global pharmaceutical company).
  • Flagship Projects:
    • CRYSVITA (burosumab): Treatment for XLH in adults and pediatrics. Recently expanded reimbursement in Canada.
    • KOMZIFTI (ziftomenib): Menin inhibitor for AML (NPM1-mutated). FDA approved Nov 2025; partnership with Kura Oncology.
    • Rocatinlimab: OX40-targeted therapy for atopic dermatitis. Recently regained full control from Amgen; Phase 3 data positive.
    • OTL-200: Gene therapy for MLD (Orphan designation in Japan).
Read the original news release →

More from

Jun 30, 2026 · 08:30

Rare disease and oncology specialist advancing lifecycle management for POTELIGEO, CRYSVITA, and KOMZIFTI while transitioning key dermatology assets in-house.

Other Jun 29, 2026 · 08:30

Rare disease and oncology franchise delivering consistent, incremental clinical and regulatory milestones across multiple asset portfolios.

Other Jun 23, 2026 · 08:30

Rare disease and oncology portfolio advancing with regulatory wins, expanded access, and strategic pipeline consolidation.

M&A / Property Jun 10, 2026 · 08:00

Pipeline-driven biopharma advancing rare disease and oncology franchises with incremental clinical evidence and regulatory wins.

Other May 14, 2026 · 08:30

Kyowa Kirin Expands CRYSVITA Dosing Flexibility Amidst Pipeline Momentum

Regulatory Apr 24, 2026 · 08:00

Strategic Execution of Global Ziftomenib Pipeline Following US Approval

Other